Table 1.
Demographic and microbiological data of CTX-M-harboring Escherichia coli isolates.
| ID | City | Collection Date | Source | Ward | MLST | MIC (ug/mL) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRO | CTX | CAZ | FEP | TZP | ETP | CIP | FOS | ||||||
| 1EC | Bogotá | 2011 | Urine | ER | 648 | >4 | >4 | 16 | 32 | 16/4 | ≤0.25 | >4 | ≤32 |
| 2EC | Cali | 2012 | Urine | ER | 44 | >4 | >4 | 32 | 16 | 16/4 | ≤0.25 | >4 | ≤32 |
| 3EC | Cali | 2012 | Urine | ER | 95 | >4 | >4 | 16 | 8 | 8/4 | ≤0.25 | >4 | ≤32 |
| 4EC | Cali | 2012 | Urine | ER | 131 | >4 | >4 | 16 | 8 | 4/4 | ≤0.25 | 4 | ≤32 |
| 5EC | Cali | 2012 | Urine | ER | 131 | >4 | >4 | 8 | 16 | ≤2/4 | ≤0.25 | >4 | ≤32 |
| 6EC | Cali | 2012 | Urine | ER | 155 | >4 | >4 | 1 | 4 | ≤2/4 | ≤0.25 | >4 | >128 |
| 7EC | Cali | 2012 | Urine | ER | 617 | >4 | >4 | 64 | 32 | 8/4 | ≤0.25 | >4 | ≤32 |
| 8EC | Cali | 2012 | Urine | ER | 617 | >4 | >4 | 8 | 16 | 8/4 | ≤0.25 | >4 | ≤32 |
| 9EC | Cali | 2012 | Urine | ER | 131 | >4 | >4 | 16 | 16 | 16/4 | ≤0.25 | >4 | 128 |
| 10EC | Cali | 2012 | Urine | ER | 44 | >4 | >4 | 64 | 32 | 16/4 | ≤0.25 | >4 | ≤32 |
| 11EC | Cali | 2012 | Urine | ER | 131 | >4 | >4 | 4 | 4 | 4/4 | ≤0.25 | >4 | ≤32 |
| 12EC | Cali | 2012 | Urine | ER | 405 | >4 | >4 | 32 | 16 | 8/4 | ≤0.25 | >4 | 64 |
| 13EC | Cali | 2012 | Urine | ER | 44 | >4 | >4 | 16 | 16 | 8/4 | ≤0.25 | >4 | ≤32 |
| 14EC | Bogotá | 2012 | Urine | ER | 131 | >4 | >4 | 16 | 32 | 8/4 | ≤0.25 | >4 | ≤32 |
| 15EC | Bogotá | 2012 | Urine | ER | 44 | >4 | >4 | 16 | 8 | 8/4 | ≤0.25 | >4 | ≤32 |
| 16EC | Ibague | 2017 | Urine | ER | 351 | >4 | >4 | >32 | 64 | 32/4 | ≤0.25 | 0.5 | ≤32 |
| 17EC * | Cucuta | 2017 | Blood | ER | 131 | >4 | >4 | 16 | 16 | ≤2/4 | ≤0.25 | >4 | ≤32 |
| 18EC | Cali | 2016 | Urine | HOSP | 648 | >4 | >4 | >32 | 32 | >128/4 | >32 | >4 | ≤32 |
| 19EC * | Barranquilla | 2017 | Blood | HOSP | 405 | >4 | >4 | 16 | 32 | 8/4 | ≤0.25 | >4 | ≤32 |
| 20EC | Pereira | 2017 | Urine | HOSP | 131 | >4 | >4 | 32 | 32 | 8/4 | ≤0.25 | >4 | ≤32 |
| 21EC | Pasto | 2017 | Urine | ER | 126 | >4 | >4 | 16 | 8 | ≤2/4 | ≤0.25 | 4 | ≤32 |
| 22EC | Ibague | 2017 | Urine | ER | 131 | >4 | >4 | 32 | 32 | 32/4 | ≤0.25 | >4 | ≤32 |
| 23EC | Bucaramanga | 2017 | Urine | ER | 212 | >4 | >4 | >32 | >64 | ≤2/4 | 8 | ≤0.25 | 64 |
| 24EC | Cucuta | 2017 | Urine | ICU | 131 | >4 | >4 | >32 | 32 | >128/4 | ≤0.25 | >4 | ≤32 |
| 25EC* | Pasto | 2017 | Blood | HOSP | 131 | >4 | >4 | 16 | 8 | 4/4 | ≤0.25 | >4 | ≤32 |
| 26EC | Ibague | 2017 | Urine | HOSP | SLV-ST 602 | >4 | 4 | 8 | 8 | ≤2/4 | ≤0.25 | ≤0.25 | 64 |
CRO: ceftriaxone, CTX: cefotaxime, CAZ: ceftazidime, ER: emergency room, FEP: cefepime, HOSP: hospitalization, ICU: intensive care unit, MIC: minimum inhibitory concentration, MLST: Multilocus Sequence Typing, TZP: piperacillin/tazobactam, ETP: ertapenem, CIP: ciprofloxacin, and FOS: fosfomycin. (*) Isolates recovered from blood samples.